
## Yuka Tanaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2160031/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 589-599.	4.2	17
2	Polymorphisms in CTLA-4 predict de novo donor specific antibody formation after kidney transplantation. Human Immunology, 2022, 83, 494-498.	2.4	4
3	Acute portal hypertension using portal vein ligation abrogates TRAIL expression of liverâ€resident NK cells. Hepatology Communications, 2022, 6, 2551-2564.	4.3	3
4	TLRâ€MyD88 signaling blockades inhibit refractory Bâ€1b cell immune responses to transplantâ€related glycan antigens. American Journal of Transplantation, 2021, 21, 1427-1439.	4.7	1
5	Development of a humanized mouse model to analyze antibodies specific for human leukocyte antigen (HLA). PLoS ONE, 2021, 16, e0236614.	2.5	4
6	Analysis of Risk Factors Affecting Incidence of Osteoporosis and Fragility Fractures in Liver Transplant Recipients. Annals of Transplantation, 2021, 26, e925475.	0.9	1
7	Molecular Mismatch Predicts T Cell–Mediated Rejection and De Novo Donorâ€6pecific Antibody Formation After Living Donor Liver Transplantation. Liver Transplantation, 2021, 27, 1592-1602.	2.4	8
8	B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4+ T cell responses in highly sensitized transplant recipients. Scientific Reports, 2021, 11, 18180.	3.3	0
9	Impacts of single nucleotide polymorphisms in Fc gamma receptor IIA ( <i>rs1801274</i> ) on lung transplant outcomes among Japanese lung transplant recipients. Transplant International, 2021, 34, 2192-2204.	1.6	4
10	Identification of Aggravation-Predicting Gene Polymorphisms in Coronavirus Disease 2019 Patients Using a Candidate Gene Approach Associated With Multiple Phase Pathogenesis: A Study in a Japanese City of 1 Million People. , 2021, 3, e0576.		2
11	Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report. Transplantation Proceedings, 2020, 52, 600-603.	0.6	0
12	Everolimus enhances TRAILâ€mediated antiâ€ŧumor activity of liver resident natural killer cells in mice. Transplant International, 2020, 33, 229-243.	1.6	8
13	Strategies for Deliberate Induction of Immune Tolerance in Liver Transplantation: From Preclinical Models to Clinical Application. Frontiers in Immunology, 2020, 11, 1615.	4.8	12
14	Impact on biliary complications of donor abdominal aortic calcification among living donor liver transplantation: a retrospective study. Transplant International, 2020, 33, 1745-1753.	1.6	10
15	Tumor Endothelial Cell–Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway. Molecular Cancer Research, 2020, 18, 1427-1440.	3.4	22
16	Management of Refractory Ascites for Liver Transplant Candidates: A Novel Cell-free and Concentrated Ascites Reinfusion Therapy. Transplantation Proceedings, 2019, 51, 2740-2744.	0.6	1
17	Utility of Doppler Ultrasonography in Liver Transplantation With Celiac Axis Compression Syndrome: A Case Report. Transplantation Proceedings, 2019, 51, 3103-3106.	0.6	3
18	Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study. PLoS ONE, 2019, 14, e0217586.	2.5	39

Υυκά Τάνακα

#	Article	IF	CITATIONS
19	Risk Factors for Refractory Ascites After Living Donor Liver Transplant. Transplantation Proceedings, 2019, 51, 1516-1519.	0.6	4
20	Cotransplantation of preactivated mesenchymal stem cells improves intraportal engraftment of islets by inhibiting liver natural killer cells in mice. American Journal of Transplantation, 2019, 19, 2732-2745.	4.7	16
21	Postoperative Portal Hypertension Enhances Alloimmune Responses after Living-Donor Liver Transplantation in Patients and in a Mouse Model. Journal of Immunology, 2019, 203, 1392-1403.	0.8	4
22	Monitoring immune response after allogeneic transplantation of mesenchymal stem cells for osteochondral repair. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, e275-e286.	2.7	7
23	Hepatic irradiation persistently eliminates liver resident NK cells. PLoS ONE, 2018, 13, e0198904.	2.5	10
24	Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients. Human Immunology, 2017, 78, 357-362.	2.4	9
25	Significant association between FOXP3 gene polymorphism and steroidâ€resistant acute rejection in living donor liver transplantation. Hepatology Communications, 2017, 1, 406-420.	4.3	10
26	Effect of Fc-Î <sup>3</sup> Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation. Transplantation Direct, 2017, 3, e164.	1.6	13
27	Viability of Airborne Tumor Cells during Excision by Ultrasonic Device. Surgery Research and Practice, 2017, 2017, 1-5.	0.5	2
28	PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice. PLoS ONE, 2017, 12, e0178765.	2.5	17
29	Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice. PLoS ONE, 2017, 12, e0186997.	2.5	13
30	Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation. Human Immunology, 2016, 77, 456-463.	2.4	17
31	Successful multidisciplinary treatment of refractory cytomegalovirus infection after living donor liver transplantation using mixed lymphocyte reactions: report of a case. Clinical Journal of Gastroenterology, 2016, 9, 38-42.	0.8	2
32	A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates. Transplantation Direct, 2015, 1, 1-6.	1.6	20
33	Fasting Enhances TRAIL-Mediated Liver Natural Killer Cell Activity via HSP70 Upregulation. PLoS ONE, 2014, 9, e110748.	2.5	6
34	Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. Human Immunology, 2014, 75, 1259-1267.	2.4	6
35	Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy. Cancer Immunology Research, 2014, 2, 1142-1147.	3.4	20
36	Adoptive Transfer of Allogeneic Liver Sinusoidal Endothelial Cells Specifically Inhibits T-Cell Responses to Cognate Stimuli. Cell Transplantation, 2013, 22, 1695-1708.	2.5	11

Υυκά Τάνακα

#	Article	IF	CITATIONS
37	Attenuation of Portal Hypertension by Continuous Portal Infusion of PGE1 and Immunologic Impact in Adult-to-Adult Living-Donor Liver Transplantation. Transplantation, 2013, 95, 1521-1527.	1.0	27
38	Evidence for the Immunosuppressive Potential of Calcineurin Inhibitor-Sparing Regimens in Liver Transplant Recipients with Impaired Renal Function. Journal of Transplantation, 2011, 2011, 1-6.	0.5	7
39	Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. Journal of Clinical Investigation, 2009, 119, 3226-35.	8.2	61
40	Role of Invariant Natural Killer T Cells in Liver Sinusoidal Endothelial Cell-Induced Immunosuppression Among T Cells with Indirect Allospecificity. Transplantation, 2008, 85, 1060-1064.	1.0	3
41	Adoptive Transfer of TRAIL-Expressing Natural Killer Cells Prevents Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy. Transplantation, 2006, 82, 1712-1719.	1.0	60
42	Liver Sinusoidal Endothelial Cells That Endocytose Allogeneic Cells Suppress T Cells with Indirect Allospecificity. Journal of Immunology, 2006, 177, 3615-3624.	0.8	40
43	Low Incidence of Acute Rejection after Living-Donor Liver Transplantation: Immunologic Analyses by Mixed Lymphocyte Reaction using a Carboxyfluorescein Diacetate Succinimidyl Ester Labeling Technique. Transplantation, 2005, 79, 1262-1267.	1.0	61
44	Liver sinusoidal endothelial cells have a capacity for inducing nonresponsiveness of T cells across major histocompatibility complex barriers. Transplant International, 2005, 18, 206-214.	1.6	29
45	Liver Sinusoidal Endothelial Cells Tolerize T Cells across MHC Barriers in Mice. Journal of Immunology, 2005, 175, 139-146.	0.8	68
46	Multiparameter Flow Cytometric Approach for Simultaneous Evaluation of Proliferation and Cytokineâ€Secreting Activity in T Cells Responding to Alloâ€stimulation. Immunological Investigations, 2004, 33, 309-324.	2.0	55
47	Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology, 2004, 39, 1321-1331.	7.3	126
48	Adoptive immunotherapy overcomes genetic susceptibility to bloodstream infections due to fcâ€gamma receptor polymorphisms after liver transplantation. American Journal of Transplantation, 0, , .	4.7	3